Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index.
Ana Ortega-FrancoClare HodgsonHaseem RajaMathew CarterColin LindsaySarah HughesLaura Cove-SmithPaul TaylorYvonne SummersFiona BlackhallRaffaele CalifanoPublished in: Targeted oncology (2022)
In our series, the outcome of pembrolizumab in pre-treated NSCLC is consistent with the registration trial. Lung Immune Prognostic Index is a readily available tool able to prognosticate outcome, also in PD-L1-high patients. The positive association between irAEs and OS might aid decision making.
Keyphrases
- advanced non small cell lung cancer
- end stage renal disease
- newly diagnosed
- decision making
- small cell lung cancer
- chronic kidney disease
- clinical trial
- prognostic factors
- randomized controlled trial
- big data
- patient reported outcomes
- phase iii
- epidermal growth factor receptor
- brain metastases
- open label
- patient reported